文献速递免疫规划

通过控制释放嵌合异种串联M2序列的去毒细菌外膜囊泡实现单剂长效大流行流感疫苗

A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles.
PubMed 文献 · Vaccine · 2017-08-31

研究描述一种基于重组外膜囊泡(rOMVs)的单剂流感疫苗,其展示甲型流感病毒M2蛋白的异种串联序列,并从聚乳酸-羟基乙酸共聚物(PLGA)微粒中释放超过30天。BALB/c小鼠接种4周后产生高抗M2e IgG滴度,10周后致死剂量PR8(H1N1)攻击存活率100%,6个月后仍维持100%存活。

要点

  • 单剂rOMV微粒疫苗在BALB/c小鼠中诱发的抗M2e IgG滴度相当于典型初免/加强方案8周时的水平。
  • 接种后10周致死剂量PR8攻击,单剂微粒疫苗组与初免/加强组小鼠存活率均为100%。
  • 单剂微粒疫苗组脾细胞受M2e肽刺激产生高IFNγ相对IL-4,支持Th1偏向免疫应答。

核心结论

  • 这些数据支持控制释放rOMVs作为有效单剂、长效且快速起效的流感疫苗的潜力。

研究设计与样本

  • 研究使用展示甲型流感病毒M2蛋白异种串联序列的重组外膜囊泡(rOMVs),从PLGA微粒中释放超过30天。
  • 在BALB/c小鼠中评价单剂rOMV微粒疫苗与初免/加强疫苗方案,并以致死剂量鼠适应流感病毒PR8(H1N1)攻击。

主要发现

  • 接种4周后,BALB/c小鼠产生高抗M2e IgG滴度,相当于典型初免/加强疫苗方案8周时产生的滴度。
  • 接种后10周以致死剂量PR8(H1N1)攻击,rOMV单剂微粒疫苗组与初免/加强疫苗组小鼠存活率均为100%。
  • 抗M2e IgG1和IgG2a抗体滴度偏向IgG1,但rOMV单剂微粒疫苗组小鼠脾细胞受M2e肽刺激产生高IFNγ相对IL-4。
  • 保护性免疫应答持久,初次接种6个月后小鼠仍维持抗体滴度,且以致死剂量PR8攻击后存活率100%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The influenza A virus undergoes genetic drift and shift, leaving the general population susceptible to emerging pandemic strains, despite seasonal flu vaccination. Here we describe a single dose influenza vaccine derived from recombinant outer membrane vesicles (rOMVs) that display an antigen-mapped heterospecies tandem sequence of the M2 protein from the influenza A virus, released over 30days from poly(lactic-co-glycolide) (PLGA) microparticles. Four weeks post vaccination, BALB/c mice developed high anti-M2e IgG titers that were equivalent to those generated at 8weeks in a typical prime/boost vaccine regimen. Challenge of mice with a lethal dose of mouse adapted influenza virus PR8 (H1N1) 10weeks post vaccination resulted in 100% survival for both rOMV single-dose microparticle and prime/boost vaccinated mice. Anti-M2e IgG1 and IgG2a antibody titers were weighted toward IgG1, but splenocytes isolated from rOMV single-dose microparticle vaccinated mice produced high levels of IFNγ relative to IL-4 in response to stimulation with M2e peptides, supporting a more Th1 biased immune response. The protective immune response was long lasting, eliciting sustained antibody titers and 100% survival of mice challenged with a lethal dose of PR8 six months post initial vaccination. Together, these data support the potential of controlled release rOMVs as an effective single dose, long lasting and rapidly effective vaccine to protect against influenza.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Watkins HC, Pagan CL, Childs HR, et al. A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles. Vaccine. 2017. PMID: 28866291. doi:10.1016/j.vaccine.2017.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。